Abeona Plans New Phase 3 Trial as ZEVASKYN Rollout Expands

By Tom Whitfield

Abeona Therapeutics plans an estimated $50 million to $60 million development program for ABO-801 over roughly 2.5 years, after two Phase 3 studies each missed a co-primary endpoint measuring patient-reported symptoms. CEO Vish Seshadri presented the next study at a Stifel investor event.

What changes after two missed symptom endpoints?

Two Phase 3 studies evaluated ABO-801, previously known as APT-1011, and each missed a co-primary endpoint measuring patient-reported symptoms. Seshadri said the company believes “changes to the study design could improve the chances of a successful trial.” Abeona acquired the asset after reviewing dozens of potential candidates, and the deal should not disrupt ZEVASKYN commercialization or supply.

Seshadri attributed the missed symptom endpoints partly to the patient-reported outcome tool used in the earlier trials. Abeona plans to use the Dysphagia Symptom Questionnaire, or DSQ, which asks whether a patient ate solid food before proceeding with symptom questions. The company will size the study to detect an approximately 13-percentage-point difference in complete response.

A 12-week endpoint will assess response, with a 24-week durability confirmation. The company also plans to adjust the patient mix to include more people with moderate or severe disease.

Seshadri cautioned that the retrospective mapping of earlier trial results to the DSQ relies on assumptions and cannot support a regulatory submission on its own.

Takeaway: The redesign addresses the earlier measurement problem, but it does not erase the two missed endpoints.

What does the earlier evidence show?

ABO-801 uses an orally dissolving formulation of fluticasone propionate to treat eosinophilic esophagitis, or EoE, an inflammatory disease of the esophagus. The drug holds orphan drug designation, and its formulation and method-of-use patents extend to 2042.

Seshadri cited histological and endoscopic results from the earlier studies as evidence of potential. A pooled analysis also showed a statistically significant difference in complete symptom response: 18% of treated patients reported no difficulty swallowing during a specified 14-day period, compared with 6% of the control group.

Takeaway: Histology, endoscopy and pooled-response figures support another test, but the earlier symptom failures remain the central risk.

How is ABO-801 financed, and how much runway remains?

Chief Financial Officer Joe Vazzano said Abeona issued $20 million in company stock to Ellodi as part of the acquisition and paid no cash upfront. Vazzano said the first milestone payment “would not be due until ABO-801 is approved.”

Abeona held more than $135 million in cash at Sept. 30, excluding $30 million in PIPE proceeds. Vazzano said that cash, ZEVASKYN revenue and FAYUVI royalties would provide sufficient capital for the estimated $50 million to $60 million development program over roughly 2.5 years.

Abeona expects to add a handful of specialists for ABO-801 while using existing clinical-operations personnel. The ZEVASKYN commercial and manufacturing teams will remain focused on that product.

Takeaway: The deal uses stock rather than upfront cash, while revenue and royalties still carry part of the development burden.

How far has the ZEVASKYN rollout progressed?

Abeona treated six patients with ZEVASKYN in the third quarter, raising the total to 15 since the December launch. The FDA approved the product in 2025.

Eight qualified treatment centers now operate across the United States, and four have treated patients. Seshadri said Abeona wants all eight to treat their first patient by around the middle of next year.

Center delays reflect several factors, including out-of-state Medicaid enrollment and clinical issues affecting patients initially selected for treatment. Chief Commercial Officer Madhav Vasanthavada said Abeona is speaking with additional centers and expects a few more to come online in 2027.

Takeaway: Abeona has treated 15 patients, but center delays leave only four of eight active sites with treated patients.

What are physicians asking before wider use?

Requested follow-up before physicians treat subsequent patients ranges from three months to about six months. Vasanthavada said physicians are sharing wound-healing observations in confidential advisory settings, and some have expressed interest in a more formal scientific forum.

Takeaway: The observations remain advisory, and physicians still want three to six months before treating subsequent patients.

What does Abeona's existing lead product treat?

Abeona Therapeutics, listed on Nasdaq as ABEO, develops cell and gene therapies for serious and rare diseases, with a focus on treatments that address underlying genetic causes. Its lead product, ZEVASKYN, treats recessive dystrophic epidermolysis bullosa, a rare inherited skin disorder.

ZEVASKYN, or prademagene zamikeracel, is an autologous gene-corrected cell therapy. It uses skin cells from the patient and genetic modification to help cells produce type VII collagen; Abeona applies the therapy to wounds.

Takeaway: Abeona now funds a redesigned oral program while commercializing a gene-corrected treatment for a rare skin disease.